Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ensayo fase Ib de aumento de dosis de taselisib (GDC-0032) en combinación con terapias anti-HER2 en participantes con cáncer de mama HER2+ avanzado

21 de septiembre de 2026 actualizado por: Nancy Lin, MD

This research study is a way of gaining new knowledge about the combination of Taselisib with other drugs in the treatment of metastatic breast cancer. Taselisib is an investigational drug which works by blocking a protein called PI3K (phosphoinositide 3-kinase) that helps cancer cells grow. This drug has been used in laboratory experiments and information from these studies suggests that this drug may help to prevent or slow the growth of cancer cells. The main purpose of this study is to find the appropriate dose of Taselisib to be used with other drugs in further clinical studies. This is an open-label, 3+3 dose-escalation phase Ib study to identify the Maximum Tolerated Dose(s) (MTD) and to identify the recommended phase 2 dose (RP2D) of Taselisib. This study will be conducted in 4 separate arms. (A-D).

Descripción general del estudio

Descripción detallada

This study is divided in two parts, a combination dose finding escalation part (Part 1) and a dose combination expansion part (Part 2). Participants will enter only one Part (either 1 or 2) and receive study drugs from only one combindation of study drugs, know as arms, as assigned by the main study physician. The study includes four different arms as listed below:

  • Arm A: Taselisib with Trastuzumab emtansine (also called T-DM1)
  • Arm B: Taselisib with Trastuzumab emtansine and Pertuzumab
  • Arm C: Taselisib with Pertuzumab and Trastuzumab
  • Arm D: Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel

Part 1: Since we are looking for the highest dose of Taselisib that can be administered safely without severe or unmanageable side effects in participants that have breast cancer, not everyone who participates in Part 1 of this research study will receive the same dose of the Taselisib. The dose participants get will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses.

Each combination dose will only be given to a group of 3 - 6 participants. The results from each group will be reviewed and depending on the results, a different combination dose or schedule may be investigated in the next group of participants or the same combination dose taken by a participant may be repeated with the next group of participants to investigate these results further (a different schedule means that instead of taking doses once every day, participants may take them only on some days in the week).

Part 2: The doses in this part will be based on the best combination doses from Part 1. This part will look at the potential side effects and see how your cancer responds to the drug.

Tipo de estudio

Intervencionista

Inscripción (Actual)

68

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02215
        • Dana Farber Cancer Institute
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Sarah Cannon Research Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Metastatic, locally advanced , or locally recurrent breast cancer

  • Histologically confirmed HER2+ invasive breast cancer

  • Measurable or non-measurable disease per RECIST v1.1

  • Prior therapy - Prior trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1) are allowed. Patients who have received prior therapy with Taselisib (GDC-0032) or BYL-719 are excluded. There is no limit on the number of prior lines of therapy.

  • ECOG performance status 0 or 1

  • Normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1,500/mm3
    • Platelets ≥100,000/mm3
    • Total bilirubin < 1.5 X institutional upper limit of normal. For patients with Gilbert syndrome, the direct bilirubin should be within the institutional normal range
    • AST (SGOT) and ALT (SGPT) < 2.5 X institutional upper limit of normal
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min
    • Fasting glucose ≤ 120 mg/dL and HbA1c < 7%
  • Left ventricular ejection fraction ≥ 50%

  • Women of childbearing potential (including those who have had a tubal ligation) must have a documented negative pregnancy test within 14 days prior to planned initiation of Taselisib.

  • Ability to understand and the willingness to sign a written informed consent document.

  • For Part 2: patients must have tissue that is amenable to biopsy and must be willing to undergo research biopsy. Patients who undergo an attempted research biopsy procedure for the purpose of this protocol, and in whom inadequate tissue is obtained, are not required to undergo a repeat biopsy in order to continue on protocol.

Exclusion Criteria:

  • Anti-cancer therapy within 2 weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than 2 weeks earlier. Palliative radiation to bony metastases ≥2 weeks prior to study entry is allowed.

  • Prior treatment with a PI3 kinase, AKT or mTOR inhibitor in which the patient experienced a Grade ≥3 drug related adverse event or otherwise would be at increased risk for additional PI3K related toxicity

  • Currently receiving any other investigational agents. Treatment with an investigational agent within 2 weeks prior to planned initiation of study therapy is allowed provided that any drug related toxicity has completely resolved

  • Major surgical procedure within 4 weeks prior to planned initiation of study therapy

  • Significant traumatic injury within 3 weeks prior to planned initiation of study therapy

  • Known untreated brain metastases are excluded. History of treated CNS metastases is okay, provided the following criteria are met:

    • Disease outside the CNS is present.
    • No evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study
    • No history of intracranial hemorrhage or spinal cord hemorrhage
    • Not requiring anti-convulsants for symptomatic control
    • Minimum of 3 weeks between completion of CNS radiotherapy and Cycle 1 Day 1 and recovery from significant (Grade ≥ 3) acute toxicity with no ongoing requirement for corticosteroid
  • History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to the Taselisib drug formulation or other agents used in this study.

  • Receiving any medications or substances that are inhibitors of CYP3A4.

  • Malabsorption syndrome or other condition that would interfere with enteral absorption

  • Active small or large intestine inflammation such as Crohn's disease or ulcerative colitis

  • Type 1 or 2 diabetes requiring anti hyperglycemic medication (e.g. metformin, glipizide, insulin)

  • Leptomeningeal disease as the only manifestation of the current malignancy

  • Congenital long QT syndrome or QTc > 500 msec

  • Active congestive heart failure or ventricular arrhythmia requiring medication

  • Uncontrolled ascites requiring weekly large volume paracentesis for 2 consecutive weeks prior to initiation of study treatment

  • Active infection requiring intravenous (IV) antibiotics

  • Patients requiring any daily supplemental oxygen

  • Uncontrolled hypomagnesemia, hypokalemia or hypocalcemia, defined as values below the lower limit of normal (LLN) for the institution despite adequate electrolyte supplementation or management

  • Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy

  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis

  • Grade ≥2 peripheral neuropathy

  • Any other diseases, active or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, pulmonary dysfunction, metabolic dysfunction, psychiatric illness/social situations, physical examination finding, or clinical laboratory finding that would limit compliance with study requirements.

  • Women of childbearing potential (< 1 year amenorrheic) or sexually active males who are not employing adequate contraception (or practicing complete abstinence).

    • Female patients of childbearing potential must commit to using a reliable and appropriate method of contraception until at least 7 months after the end of last dose of study treatment.
    • Male patients with a partner of childbearing potential must agree to use a barrier method of contraception (condom) in addition to having their partner use another contraceptive method during the trial and for 7 months after the last dose of study treatment.
  • Pregnant women and women who are lactating.

  • Known human immunodeficiency virus (HIV) infection

  • Inability or unwillingness to swallow pills

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm A

Arm A

- Taselisib with Trastuzumab emtansine (also called T-DM1)

  • Taselisib administered orally, daily in each treatment cycle (3 weeks).
  • Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).
Otros nombres:
  • GCD-0032
Otros nombres:
  • Kadcyla
  • T-DM1
Experimental: Arm B

Arm B

-Taselisib with T-DM1 and Pertuzumab

  • Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).
  • Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).
  • Pertuzumab- administered once via IV per treatment cycle (3 weeks).
Otros nombres:
  • Perjeta
Otros nombres:
  • GCD-0032
Otros nombres:
  • Kadcyla
  • T-DM1
Experimental: Arm C

Arm C:

  • Taselisib with Pertuzumab and Trastuzumab

  • Cohort C will not open without additional authorization from Genentech

    • Taselisib is administered oral, daily in each treatment cycle (3 weeks).
    • Trastuzumab administered once via IV per treatment cycle (3 weeks).
    • Pertuzumab- administered once via IV per treatment cycle (3 weeks).
Otros nombres:
  • Perjeta
Otros nombres:
  • Herceptina
Otros nombres:
  • GCD-0032
Experimental: Arm D

Arm D

  • Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel

  • Cohort will not be opened without additional authorization from Genentech

    • Taselisib- administered oral, daily in each treatment cycle (3 weeks).
    • Pertuzumab- administered once via IV per treatment cycle (3 weeks).
    • Trastuzumab administered once via IV per treatment cycle (3 weeks).
    • Paclitaxel- administered via IV, weekly for 3 weeks within each cycle.
Otros nombres:
  • Taxol
  • Onxal
Otros nombres:
  • Perjeta
Otros nombres:
  • Herceptina
Otros nombres:
  • GCD-0032

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Dosis máxima tolerada (DMT) de taselisib en combinación con terapia(s) anti-HER2 y/o paclitaxel.
Periodo de tiempo: 28 días
28 días

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Ocurrencia de reducciones de dosis
Periodo de tiempo: 2 años
2 años
Clinical Benefit Rate (CBR) for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.
Periodo de tiempo: > or = 6 Months

Defined as complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.1

> or = 6 Months
Progression Free Survival (PFS) for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.
Periodo de tiempo: 2 Years

Defined as the time from the date of the first dose of study treatment until the date of first documentation of progressive disease (PD) or death from any cause (whichever occurs first)

2 Years
Overall Survival for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.
Periodo de tiempo: 2 Years

Defined as the time from the date of the first dose of study treatment until the date of death from any cause

2 Years
Occurrence of AEs and SAEs during treatment with Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.
Periodo de tiempo: 2 Years

Defined with CTCAE version 4.0

2 Years
Occurrence of dose delays or holds
Periodo de tiempo: More than 7 Days

Defined as a delay or hold of one of the study agents for more than 7 days

More than 7 Days
Dose Limiting Toxicity of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.
Periodo de tiempo: 28 Days

Defined as a toxicity within the DLT Assessment Window.

28 Days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Nancy Lin, MD, Dana Farber Cancer Insitute

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de abril de 2015

Finalización primaria (Actual)

1 de diciembre de 2022

Finalización del estudio (Actual)

1 de julio de 2024

Fechas de registro del estudio

Enviado por primera vez

11 de marzo de 2015

Primero enviado que cumplió con los criterios de control de calidad

11 de marzo de 2015

Publicado por primera vez (Estimado)

17 de marzo de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir